Acadia Healthcare Company, Inc. (ACHC) News & EventsACHCNews & EventsAcadia Healthcare Company, Inc.

Acadia Healthcare Raises 2026 EBITDA Guidance to $30

Acadia Healthcare raised 2026 EBITDA guidance on DPP upside, but an unexpected increase in professional and general liability reserves created a near-term earnings headwind and likely pressure on shares, Cantor Fitzgerald analyst Sarah James tells investors in a research note. The firm maintains a Neutral rating and $30 price target on the shares.

FY26 Revenue Outlook Narrowed to $3.4B-$3.45B

Consensus $1.52. Narrows FY26 revenue view to $3.4B-$3.45B from $3.37B-$3.45B, consensus $3.4B

Acadia Reports Q2 Revenue of $865.8M, Beating Expectations

Reports Q2 revenue $865.8M, consensus $844.22M. "Acadia delivered solid results in the second quarter that were driven by our continued focus on disciplined operational execution and providing quality care for our patients," said Debbie Osteen, Chief Executive Officer of Acadia. "We made significant progress on our key priorities during the second quarter, including opening two new facilities with JV partners, continuing to ramp occupancy at our new facilities opened over the last few years, and generating strong free cash flow. We are well-positioned for additional progress in the second half of the year as we build upon our leadership position in the behavioral healthcare industry and continue expanding access to quality care for our patients."